Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database

Abstract Background Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas with poor prognosis, particularly in patients with relapsed or refractory (R/R) disease. Romidepsin and tucidinostat are histone deacetylase inhibitors used to treat R/R PTCL. No head-to-head post-marketing s...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nao Takatsu, Jun Matsumoto, Yurie Oka, Tomonori Sakai, Naohiro Iwata, Tsukasa Higashionna, Tatsuaki Takeda, Hirofumi Hamano, Yoshito Zamami
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-03-01
coleção:	Journal of Pharmaceutical Health Care and Sciences
Assuntos:	Romidepsin Tucidinostat Adverse event JADER Pharmacovigilance
Acesso em linha:	https://doi.org/10.1186/s40780-026-00565-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!